Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission
STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep will generate significant recurring revenue per procedure and expand the advantages of using robotics in EP.
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval
Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Stock Market Sleeps On Stereotaxis MAGiC CE Mark
Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. This will further drive recurring revenue and stock momentum. GenesisX's first order was announced. A successful practice will be pivotal for future orders which should begin after the commercial launch at the EHRA Congress in March/April.
STXS Stock Gains Following the First Order for its GenesisX
Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturing of its robotic mapping and guidecatheter for regulatory submissions in Q1 2025. STXS's holistic ecosystem approach, including interventional devices, GenesisX, and digital surgery advancements, aims to solve long-standing issues with robotic adoption in EP.
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - TD Cowen Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis Third Quarter 2024 Earnings Conference Call.
Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
